Allurion Technologies has begun training and onboarding partner accounts across the United States, including large academic medical centers and private practices, following the company’s FDA approval of the Allurion Gastric Balloon System on February 23, 2026. The company expects to start shipping the swallowable balloon and its virtual care suite in April.
The move marks a transition from a development phase to active commercial deployment in the world’s largest obesity‑treatment market. By building a network of U.S. providers, Allurion aims to deliver its balloon and care platform to patients who have discontinued GLP‑1 medications, creating a new pathway for weight‑loss therapy.
Allurion’s financial backdrop shows a challenging but evolving picture. Q3 2025 revenue was $2.7 million, a 50 % decline from Q3 2024, while Q4 2024 revenue was $5.6 million, down from $8.2 million the prior year. The company carries $83 million in debt and has a market capitalization of approximately $16.7 million, underscoring the need for disciplined growth as it scales operations.
Dr. Shantanu Gaur, Founder and CEO, said, “We believe Allurion has a unique opportunity to fill an important gap in the U.S. market with a solution that is clinically proven, accessible, and can seamlessly integrate into existing practices.” He added, “In just the first weeks of engaging with customers and partners across the country, the feedback has been overwhelmingly positive. Providers are excited about offering their patients a proven, noninvasive weight‑loss therapy either as an alternative or complement to their GLP‑1 medications. This early momentum reinforces our belief that Allurion can make a meaningful impact in the lives of millions of Americans.”
The competitive landscape is intensifying. The GLP‑1 market is projected to grow to hundreds of billions of dollars by the mid‑2030s, with major players such as Novo Nordisk and Eli Lilly. Allurion’s balloon offers a non‑surgical alternative that can be used alone or alongside GLP‑1s, targeting the estimated 20 million Americans who have started and stopped GLP‑1 therapy—a number expected to rise to 40 million by 2027.
The U.S. launch positions Allurion to capture a share of the obesity‑treatment market, but the company must navigate its debt load and revenue growth challenges. The training and onboarding initiative signals readiness to meet demand and scale the program nationwide, while the company continues to focus on cost control and market penetration to strengthen its financial footing.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.